The FDA Comes Around
We believe innovation in the health care sector is accelerating in part due to a more accommodating regulatory environment for disruptive technologies. Often perceived as a regulatory roadblock, the Food and Drug Administration, or FDA, has become a facilitator of this innovation.



The views expressed are the views of Fred Alger Management, Inc. and Fred Alger & Company, Incorporated (“Alger”) as of February 2019. Alger has used sources of information which it believes to be reliable; however, this publication is not intended to be and does not constitute investment advice. These views are subject to change at any time and they do not guarantee the future performance of the markets, any security, or any funds managed by Alger.

This presentation is provided in Israel only to investors of the type listed in the first schedule of the Securities Law, 1968 (the "Securities Law") and the Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management Law, 1995. The fund units will not be sold to investors who are not of the type listed in the first schedule of the Securities Law.

Risk Disclosures: Investing in the stock market involves gains and losses and may not be suitable for all investors. Growth stocks tend to be more volatile than other stocks as the prices of growth stocks tend to be higher in relation to their companies’ earnings and may be more sensitive to market, political and economic developments. Past performance is no guarantee of future results. Please visit www.alger.com for additional risk disclosures.    

Fred Alger & Company, Incorporated 360 Park Avenue South, New York, NY 10010 / www.alger.com





     

​​​​ 

MATTHEW MARGOLIS​​
Vice President, Analyst


Click here to download the transcript ​


CLICK HERE to learn more about the Alger Health Sciences Fund​